ES2662611T3 - Variantes solubles e inmunorreactivas del antígeno p24 de la cápside de HTLV - Google Patents
Variantes solubles e inmunorreactivas del antígeno p24 de la cápside de HTLV Download PDFInfo
- Publication number
- ES2662611T3 ES2662611T3 ES15706804.0T ES15706804T ES2662611T3 ES 2662611 T3 ES2662611 T3 ES 2662611T3 ES 15706804 T ES15706804 T ES 15706804T ES 2662611 T3 ES2662611 T3 ES 2662611T3
- Authority
- ES
- Spain
- Prior art keywords
- htlv
- antigen
- ctd
- protein
- fkpa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000036639 antigens Human genes 0.000 title abstract description 46
- 239000000427 antigen Substances 0.000 title abstract description 45
- 108091007433 antigens Proteins 0.000 title abstract description 44
- 101710147327 Calcineurin B homologous protein 1 Proteins 0.000 title abstract description 36
- 101710205625 Capsid protein p24 Proteins 0.000 title abstract description 36
- 101710177166 Phosphoprotein Proteins 0.000 title abstract description 36
- 101710149279 Small delta antigen Proteins 0.000 title abstract description 36
- 241000598436 Human T-cell lymphotropic virus Species 0.000 title abstract description 35
- 210000000234 capsid Anatomy 0.000 title 1
- 108010006519 Molecular Chaperones Proteins 0.000 abstract description 12
- 210000004899 c-terminal region Anatomy 0.000 abstract description 2
- 108090000623 proteins and genes Proteins 0.000 description 23
- 102000004169 proteins and genes Human genes 0.000 description 23
- 235000018102 proteins Nutrition 0.000 description 18
- 230000004927 fusion Effects 0.000 description 17
- 238000001514 detection method Methods 0.000 description 15
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 15
- 229920001184 polypeptide Polymers 0.000 description 13
- 108090000765 processed proteins & peptides Proteins 0.000 description 13
- 102000004196 processed proteins & peptides Human genes 0.000 description 13
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical group N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 12
- 238000003018 immunoassay Methods 0.000 description 11
- 238000002983 circular dichroism Methods 0.000 description 10
- 101800000385 Transmembrane protein Proteins 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 239000007790 solid phase Substances 0.000 description 8
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- 229960002685 biotin Drugs 0.000 description 6
- 235000020958 biotin Nutrition 0.000 description 6
- 239000011616 biotin Substances 0.000 description 6
- 238000001142 circular dichroism spectrum Methods 0.000 description 6
- 108020001507 fusion proteins Proteins 0.000 description 6
- 102000037865 fusion proteins Human genes 0.000 description 6
- 102000005431 Molecular Chaperones Human genes 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 description 4
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 4
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 4
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 229910000160 potassium phosphate Inorganic materials 0.000 description 4
- 235000011009 potassium phosphates Nutrition 0.000 description 4
- 229910052707 ruthenium Inorganic materials 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- 241000714259 Human T-lymphotropic virus 2 Species 0.000 description 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 101800001271 Surface protein Proteins 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000008033 biological extinction Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000000978 circular dichroism spectroscopy Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 230000036046 immunoreaction Effects 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000012460 protein solution Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 108010078428 env Gene Products Proteins 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 230000006432 protein unfolding Effects 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 150000003303 ruthenium Chemical class 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000009589 serological test Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 230000010512 thermal transition Effects 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- G01N33/56988—HIV or HTLV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
- C12N2740/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
- C12N2740/14031—Uses of virus other than therapeutic or vaccine, e.g. disinfectant
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
- C12N2740/14051—Methods of production or purification of viral material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- AIDS & HIV (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14157165 | 2014-02-28 | ||
| EP14157165.3A EP2913338A1 (en) | 2014-02-28 | 2014-02-28 | Soluable and immunoreactive variants of HTLV capsid antigen p24 |
| PCT/EP2015/053966 WO2015128394A2 (en) | 2014-02-28 | 2015-02-26 | Soluble and immunoreactive variants of htlv capsid antigen p24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2662611T3 true ES2662611T3 (es) | 2018-04-09 |
Family
ID=50184798
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES15706804.0T Active ES2662611T3 (es) | 2014-02-28 | 2015-02-26 | Variantes solubles e inmunorreactivas del antígeno p24 de la cápside de HTLV |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US10466242B2 (enExample) |
| EP (2) | EP2913338A1 (enExample) |
| JP (1) | JP6491228B2 (enExample) |
| CN (1) | CN106029687B (enExample) |
| CA (1) | CA2938712C (enExample) |
| ES (1) | ES2662611T3 (enExample) |
| WO (1) | WO2015128394A2 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108780092A (zh) | 2016-03-07 | 2018-11-09 | 豪夫迈·罗氏有限公司 | 抗p53抗体的检测 |
| WO2019164402A1 (en) * | 2018-02-26 | 2019-08-29 | Technische Universiteit Eindhoven | Bioluminescent biosensor for detecting and quantifying biomolecules |
| JP2023522278A (ja) * | 2020-04-23 | 2023-05-29 | エフ． ホフマン－ラ ロシュ アーゲー | 抗体－免疫アッセイでの使用のためのコロナヌクレオカプシド抗原 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2564268B2 (ja) * | 1985-08-28 | 1996-12-18 | 協和醗酵工業株式会社 | 融合抗原ポリペプチド |
| NZ238855A (en) | 1990-07-18 | 1994-03-25 | Iaf Biochem Int | Peptides, mixtures thereof and compositions useful for detecting htlv-i and htlv-ii infections |
| CA2117378C (en) * | 1992-02-24 | 2003-04-15 | Steven K. H. Foung | Htlv-i/htlv-ii assay and method |
| CA2223235A1 (en) * | 1995-06-05 | 1996-12-12 | Abbott Laboratories | Detection of htlv antibodies utilizing recombinant proteins |
| AU736670B2 (en) | 1996-09-26 | 2001-08-02 | Medical Research Council | Chaperone fragments |
| JP2000078973A (ja) * | 1998-09-03 | 2000-03-21 | Tonen Corp | Ｈｔｌｖ−ｉ組換え抗原 |
| PL354122A1 (en) * | 1999-08-09 | 2003-12-29 | Tripep Abtripep Ab | Pharmaceutical compositions containing tripeptides |
| US6258932B1 (en) * | 1999-08-09 | 2001-07-10 | Tripep Ab | Peptides that block viral infectivity and methods of use thereof |
| PL215170B1 (pl) | 2001-06-22 | 2013-10-31 | Hoffmann La Roche | Sposób wytwarzania rozpuszczalnego kompleksu zawierajacego amyloidogenne bialko docelowe oraz bialko opiekuncze z klasy izomeraz peptydyloprolilowych |
| DK2112158T3 (da) * | 2007-04-20 | 2012-01-23 | Hoffmann La Roche | Påvisning af primære infektioner med patogener |
| EP2127678A1 (en) * | 2008-05-26 | 2009-12-02 | Roche Diagnostics GmbH | SlpA as a tool for recombinant protein and enzyme technology |
-
2014
- 2014-02-28 EP EP14157165.3A patent/EP2913338A1/en not_active Ceased
-
2015
- 2015-02-26 CA CA2938712A patent/CA2938712C/en active Active
- 2015-02-26 EP EP15706804.0A patent/EP3110831B1/en active Active
- 2015-02-26 JP JP2016553811A patent/JP6491228B2/ja active Active
- 2015-02-26 WO PCT/EP2015/053966 patent/WO2015128394A2/en not_active Ceased
- 2015-02-26 CN CN201580010787.2A patent/CN106029687B/zh active Active
- 2015-02-26 ES ES15706804.0T patent/ES2662611T3/es active Active
-
2016
- 2016-08-25 US US15/246,607 patent/US10466242B2/en active Active
-
2019
- 2019-09-20 US US16/577,175 patent/US11567079B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US10466242B2 (en) | 2019-11-05 |
| JP6491228B2 (ja) | 2019-03-27 |
| EP3110831B1 (en) | 2018-01-10 |
| WO2015128394A2 (en) | 2015-09-03 |
| US20200033342A1 (en) | 2020-01-30 |
| CA2938712C (en) | 2018-10-23 |
| JP2017512200A (ja) | 2017-05-18 |
| CA2938712A1 (en) | 2015-09-03 |
| EP2913338A1 (en) | 2015-09-02 |
| CN106029687B (zh) | 2020-07-31 |
| CN106029687A (zh) | 2016-10-12 |
| EP3110831A2 (en) | 2017-01-04 |
| WO2015128394A3 (en) | 2015-11-05 |
| US11567079B2 (en) | 2023-01-31 |
| US20170184591A1 (en) | 2017-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2339709T3 (es) | Anticuerpo monoclonal anti-nucleo de vhc. | |
| ES2409631T3 (es) | Métodos para la detección simultánea de antígenos del VHC y anticuerpos para el VHC | |
| ES2662611T3 (es) | Variantes solubles e inmunorreactivas del antígeno p24 de la cápside de HTLV | |
| BRPI0210598B8 (pt) | processos para a produção de um complexo solúvel que compreende uma proteína amiloidogênica alvo e uma chaperona peptidil-prolil-isomerase, para a produção de um complexo de glicoproteína retroviral de superfície-chaperona solúvel, e para detectar pelo menos um anticorpo para uma glicoproteína retroviral de superfície em uma amostra, bem como complexo solúvel, e composição | |
| ES2981438T3 (es) | Novedosos antígenos proteicos de la envoltura del virus de la inmunodeficiencia humana expresados en mamíferos | |
| NO173958B (no) | Fremgangsmaate for paavisning av tilstedevaerelse av antistoff mot hiv-virus | |
| Bhatnagar et al. | Evaluation of multiple antigenic peptides based on the Chikungunya E2 protein for improved serological diagnosis of infection | |
| KR950701684A (ko) | 뎅그열 바이러스 혈청형 1(싱가폴균주)의 cDNA서열(cDNA sequence of dengue virus serotype 1(Singapore strain)) | |
| JP6908299B2 (ja) | サンプル中のフラビウイルスに特異的なＩｇＭ抗体の検出方法 | |
| JP2015529211A (ja) | イムノアッセイの干渉の低減、及び安定化のためのシャペロン−シャペロン融合ポリペプチド | |
| US7074555B2 (en) | Detection of West Nile Virus | |
| US7776546B2 (en) | Method and device for detecting feline immunodeficiency virus | |
| AU652919B2 (en) | Cysteine thiol-protected peptides for use in immunoassays | |
| CN114478716B (zh) | 一种多肽组合及其在新型冠状病毒抗体检测中的应用 | |
| ES2623891T3 (es) | Variantes de la lipoproteína 15 (Lp15) de Vibrio cholerae como aditivo anti-interferencia en inmunoensayos basados en TpN17 para la detección de anticuerpos anti-Treponema | |
| Verma et al. | A bio-safe multiple antigenic peptide (MAP) enzyme-linked immunoassay for the detection of antibodies to infectious bronchitis virus in chickens | |
| EP3147294B1 (en) | Distinguishing dengue virus infections from other flaviviral infections using a recombinant mutant envelope protein | |
| BJ Reddy et al. | Expression, purification and evaluation of diagnostic potential and immunogenicity of dengue virus type 3 domain III protein | |
| ES2356383T3 (es) | Expresión recombinante de variantes de proteína de cubierta de rubeola e1 como proteínas de fusión chaperonas, y utilización de las mismas en la detección de anticuerpos anti-rubeola. | |
| WO2008034297A1 (en) | Method of detecting antibodies against a series of human immunodeficiency virus proteins | |
| JP2007526919A (ja) | 糖タンパク質ｇ２ペプチドを用いたｈｓｖ−２型特異的免疫検定 | |
| WO2006098849A2 (en) | Method and device for detecting feline immunodeficiency virus | |
| HK1229824B (zh) | Htlv衣壳抗原p24的可溶性和免疫反应性变体 | |
| HK1229824A1 (en) | Soluble and immunoreactive variants of htlv capsid antigen p24 | |
| AU614971B2 (en) | Hiv polypeptide, its preparation and use in detection of hiv antibodies |